New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

Air trapping can occur in people with lung conditions such as asthma or chronic obstructive pulmonary disease (COPD). Diseases like these can damage the lungs, leaving them unable to deflate fully.

Chronic obstructive lung disease (COPD) is an umbrella term describing two different types of lung diseases. COPD affects about 27 million Americans. One in five Americans over the age of 45 years old ...

imperial.ac.uk Rationale Heart failure (HF) management in chronic obstructive pulmonary disease (COPD) is often delayed or suboptimal. Objectives To examine the effect of HF and HF medication use on ...

hli.ubc.ca Background There is limited data on the risk factors and phenotypical characteristics associated with spirometrically confirmed COPD in never-smokers in the general population. Aims To ...